Neurogastrx
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
52-60 Woburn, Woburn, Massachusetts, 018...Phone Number
(781) 730-4606Website
www.neurogastrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Neurogastrx
Founded in 20017 Neurogastrx, is a pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. Neurogastrx is located in MassachusettsExplore more
Neurogastrx Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurogastrx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Neurogastrx is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neurogastrx launches new products
Click to see if Neurogastrx had a recent Job posting/layoffs
Neurogastrx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Neurogastrx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Neurogastrx recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Neurogastrx has new funding data
Congratulate Masked Content for being promoted to Masked Content at Neurogastrx
Recommended Actions
Find VP level buyers at Neurogastrx
Find 3 more new buyers
Compare Similar Companies to Neurogastrx
Compare insights from companies similar to Neurogastrx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neurogastrx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurogastrx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurogastrx.
Neurogastrx financials insights
Gather financial insights about Neurogastrx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$45M
2021
Series B
$60M
Neurogastrx Tech Stack
A closer look at the technologies used by Neurogastrx
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Open Position
New Hire
Executive Move
Left Company
Management Move
Neurogastrx News & Media
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 AgonistsNeurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
WOBURN, Mass.--(BUSINESS WIRE)--Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors who also participated in the Series A financing. PrNeurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.
WOBURN, Mass., June 8, 2021 /PRNewswire/ -- Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today that it has entered into an exclusive license agreement with Daewoong Pharmaceutical Co....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurogastrx
Sign Up For FreeTo access detailed company insights
Founded in 20017 Neurogastrx, is a pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. Neurogastrx is located in Massachusetts... Read More
